OpenEvidence
For a US clinician this is the obvious free alternative to a general chatbot: the answers cite the journals you would cite yourself, the licensed NEJM and JAMA text is something ChatGPT cannot legally see, and it costs nothing. The trade is that the business model is pharmaceutical advertising inside a clinical tool, and the service is closed to everyone without a US professional identifier.
Pros
- Every claim carries a citation, with licensed full text from NEJM, JAMA, Nature and Cochrane rather than abstracts
- Free with no paid tier, and CME credit accrues from ordinary use
- Evidence grading shows how strong the support for an answer is
- Mobile apps add ambient documentation and voice mode for use during consultations
Cons
- Revenue is pharmaceutical advertising placed next to clinical answers, a conflict worth keeping in view
- US-only verification shuts out clinicians elsewhere, and the guideline corpus leans US practice
- The site refuses automated access and the vendor publishes little about accuracy on complex cases
- No API or integration path for health systems that want it inside the EHR